InvestorsHub Logo
Followers 22
Posts 1671
Boards Moderated 0
Alias Born 12/12/2006

Re: TOB post# 1951

Wednesday, 01/23/2013 3:00:33 PM

Wednesday, January 23, 2013 3:00:33 PM

Post# of 5881
IC-107 being their flagship product and most promising (so far), I expect $4 to $5 short term. It will greatly help to validate their dendritic cell based immunotherapy. If DNDN is north of $6 with their Gen 1 platform, IMUC should deserve better.